various amount of mRNA of luciferase or green fluorescent protein (GFP) into mouse knee joints. The luciferase mRNA expression was visualized at different time points by the IVIS imaging system. GFP expression was analyzed in histological sections. For mRNA introduction into OA cartilages, OA was induced by surgically transecting the medial collateral ligament and removing the medial meniscus in knee joints of 8-week old male C57BL/6 mice. A month after the surgery, the development of OA was confirmed by safranin-O staining and the OARSI scoring system. We then injected 10 ml solution of polyplex nanomicelles carrying mRNA of interest into OA knee joints every other day or once every 4 days for 2 weeks. Results: In vivo imaging of luciferase activities revealed that intraarticular injections of polyplex nanomicelles carrying luciferase mRNA induced the production of functional luciferase proteins around the knee joints in mice. Luciferase activities were observed at 24 hours after injection and they were maintained for more than 4 days. When we injected polyplex nanomicelles carrying GFP into intact and surgicallyinduced OA knee joints in mice, GFP expression was observed not only in both intact and OA cartilages, but also in the meniscus. There was no symptom associated with immune reactions in the mRNA injected joints. Conclusions: These results indicate that the polyplex nanomicelle successfully introduced exogenous mRNA into cells around joints, supporting the therapeutic potential of this strategy in the treatment of OA. mRNA introduction will enable us to utilize transcription factors for the treatment of degenerative diseases in disease stage-specific manners. Thus, this is an important initial step of the development of mRNA introduction-based therapeutic strategies for OA. Purpose: The purpose was to study chondrogenesis of adult human Bone Marrow Mesenchymal Stem Cells (hBMSCs) when culture on collagen (Col) biomaterials. Furthermore, we evaluated the usefulness of the generated chondrogenic constructs to repair cartilage in an in vitro lesion model. Methods: hBMSCs were cultured during 30 days in chondrogenic medium, with Transforming growth factor b-3 (TGFb-3), and in a control of DMEM medium on type I Col biomaterials. We have tested growth and cell morphology on the constructs by histochemical and Scanning (SEM) and Transmission (TEM) Electron Microscopy. Chondrogenic differentiation was evaluated in all the constructs by histochemical and immunohistochemistry analyses and molecular biology. 3 mm lesions were made in human cartilage biopsies and were pretreated with 10ng/ml IL-b for 24 hours. 2x10 5 BMSCs were seeded on type I Col biomaterials, introduced inside the lesion, and cultured during 30 days in chondrogenic medium with TGFb-3. Repaired tissue was evaluated by histochemistry and immunohistochemistry, and macroscopically using the ICRS scale. Results: Histology showed that hBMSCs have grown through the scaffolds, being the cell percentage higher than 75% in the chondrogenic constructs. It was observed a big amount of extracellular matrix (ECM), which showed proteoglycan and type II Col positivity in chondrogenic but not in control constructs. By measurement of relative expression levels (REL), type II Col and aggrecan gene expression was seen only in cells grown in chondrogenic medium. Electron microscopy showed a big amount of mitochondria and oval/rounded shape cells in chondrogenic samples. In the in vitro model, histochemistry showed that after 30 days, the cells filled almost the 90% of the lesion with a cellular density in the graft higher than the native cartilage (Fig. 1A, H-E) . We found integration of the neotissue with the border of the lesion. Regarding the ECM of the neotissue was a mixture of hyaline-and fibrocartilage, finding chondrocytes inside lacunas and an ECM positive for type II Col and aggrecan ( Figure 1A , COL II and AGG). In the macroscopic ICRS assessment, the score of the repair was 21 out of 24 points (Fig. 1B) . Conclusions: Data showed that hBMSCs are able to grow on Col biomaterials and differentiate to a chondrocityc-like phenotype. These chondrogenic constructs are able to repair an in vitro human cartilage lesion after a 24-hour-pretreatment with 10ng/ml IL-b. Acknowledgements: Opocrin S.P.A.; CAM (S2009/MAT-1472); CIBER-BBN; Red Gallega de Terapia Celular, Xunta de Galicia (R2014/050); GPC, Xunta de Galicia (GPC2014/048); Fundaci on Española de Reumatología (2014 grant); Fundaci on Profesor Novoa Santos. The main phenotypic hallmark of CHH is dwarfism, presumably caused by impaired growth plate development. Our preliminary data indeed show that RMRP is involved in chondrogenic differentiation; however, it is unclear via which mechanism. Viperin is an antiviral protein, located in the endoplasmic reticulum (ER; location of protein synthesis and secretion), and its mRNA is a known substrate of RNase MRP cleavage activity. As such, viperin expression has shown to be increased in CHH patient cells and during knockdown (KD, RNAi) of RNase MRP subunits, including RMRP RNA itself. As the chondrogenic function of RMRP is unclear and it is not known how mutations in RMRP cause CHH, we hypothesize that viperin functions as a chondrogenic regulator downstream of RNase MRP. Methods: To investigate the expression of viperin during chondrogenic differentiation in vivo, viperin was detected in day 1 mouse growth plates by immunohistochemistry. Expression of viperin mRNA and protein was determined by RT-qPCR / Western blot in chondrogenically differentiating ATDC5 cells in the presence or absence of 1 nM bone morphogenic protein (BMP)-2 or -7. KD of viperin expression was achieved via RNAi and protein secretion was measured upon transfection of a secretable CMVGaussia Luciferase. Results: To investigate whether viperin plays a role in developing chondrocytes in vivo, day 1 mouse growth plates were stained for viperin. Profound viperin staining was detected in hypertrophic chondrocytes. However, viperin was also expressed in a subpopulation of proliferative chondrocytes. In these cells a perinuclear staining could be observed, which is in agreement with the localization of viperin in the ER. To determine the role of viperin expression in more detail, viperin gene expression dynamics were determined during chondrogenic differentiation of ATDC5 cells. Expression of viperin mRNA and protein was first detected at day 4 in Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A148
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